StockData

Allarity Therapeutics vs Mereo BioPharma

ALLR and MREO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLR and MREO compare

Mereo BioPharma is the larger company, worth 16 times as much as Allarity Therapeutics ($219M against $13.4M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLRMREO
Size and price
Market cap$13.4M$219M
Share price$0.841$0.275
Change, 1 year−28.7%−84.6%
Change, 5 years–−85.6%
Beta (5Y)1.462.29
Employees839
StockData Score
Total score11
Valuation score00
Growth score00
Performance score00
Health score11
Dividend score00
Valuation
P/B3.8× (better)9.2×
FCF yield–−10.1%
Profitability
Return on equity−157%−76.6% (better)
Return on invested capital−957%–
Financial health
Debt / equity5.90–
Interest coverage−10.1× (better)−440.6×
Current ratio1.115.22 (better)
Altman Z-score−6.65−4.68 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield6.6%–
Shareholder yield6.6% (better)0.00%
Ownership
Held by institutions8.1%7.1%
Held by insiders6.3%0.18%
Short interest, % of float1.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.